Related references
Note: Only part of the references are listed.Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
John M. L. Ebos et al.
CANCER CELL (2009)
Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
Marta Paez-Ribes et al.
CANCER CELL (2009)
Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and proangiogenic hematopoietic cells in cancer: From biology to therapy
Balazs Dome et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2009)
Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: A Gynecologic Oncology Group study
Jennifer M. Rubatt et al.
GYNECOLOGIC ONCOLOGY (2009)
Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
Noriyuki Katsumata et al.
LANCET (2009)
Neoadjuvant chemotherapy with carboplatin and docetaxel in advanced ovarian cancer - a prospective multicenter phase II trial (PRIMOVAR)
Martin Poelcher et al.
ONCOLOGY REPORTS (2009)
Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: Implications for antiangiogenic drugs as chemosensitizing agents
Yuval Shaked et al.
CANCER CELL (2008)
Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: A trial of the California, Chicago, and princess Margaret hospital phase II consortia
Agustin A. Garcia et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: A Gynecologic oncology group study
Robert A. Burger et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer
Stephen A. Cannistra et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer
Aparna A. Kamat et al.
CANCER RESEARCH (2007)
Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up
C Rudlowski et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2006)
Repopulation of cancer cells during therapy: An important cause of treatment failure
JJ Kim et al.
NATURE REVIEWS CANCER (2005)
Antiangiogenic concentrations of paclitaxel induce an increase in microtubule dynamics in endothelial cells but not in cancer cells
E Pasquier et al.
CANCER RESEARCH (2005)
Paclitaxel 175 or 225 mg per meters squared with carboplatin in advanced ovarian cancer: A randomized trial
G Bolis et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Prognostic significance of microvessel density and vascular endothelial growth factor expression in advanced ovarian serous carcinoma
MR Raspollini et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2004)
Endothelial progenitor cells for postnatal vasculogenesis
T Asahara et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2004)
The anti-angiogenic basis of metronomic chemotherapy
RS Kerbel et al.
NATURE REVIEWS CANCER (2004)
Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels
E Fonsatti et al.
ONCOGENE (2003)
Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study
GA Omura et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere)
DS Grant et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors
HJ Kahn et al.
LABORATORY INVESTIGATION (2002)
Prognostic significance of microvessel density, vascular cuffing and vascular endothelial growth factor expression in ovarian carcinoma: a special review for clear cell adenocarcinoma
S Ogawa et al.
CANCER LETTERS (2002)
Low concentrations of paclitaxel induce cell type-dependent p53, p21 and G1/G2 arrest instead of mitotic arrest: molecular determinants of paclitaxel-induced cytotoxicity
P Giannakakou et al.
ONCOGENE (2001)
Redefining the target: Chemotherapeutics as antiangiogenics
KD Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Antiangiogenic chemotherapeutic agents
M Schirner
CANCER AND METASTASIS REVIEWS (2000)
Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: A gynecologic oncology group study
FM Muggia et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
